Patent ID: 9546182
Date: 2017-01-17
CPC Classifications: A61K,A61P,C07D,C07K

Claim:
1. A method of treating cancer characterized by over expression of PI3 kinase in a patient, the method comprising administering to said patient a therapeutically effective amount of a compound of Formula I: and stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein: the dashed lines indicate an optional double bond, and at least one dashed line is a double bond; X X X A is a 5, 6, or 7-membered carbocyclyl or heterocyclyl ring fused to X R R R R mor is selected from: wherein mor is optionally substituted with one or more R wherein the cancer is characterized by over expression of PI3 kinase and is selected from breast, ovary, cervix, prostate, testis, genitourinary tract, esophagus, larynx, glioblastoma, neuroblastoma, stomach, skin, keratoacanthoma, lung, epidermoid carcinoma, large cell carcinoma, non-small cell lung carcinoma (NSCLC), small cell carcinoma, lung adenocarcinoma, bone, colon, adenoma, pancreas, adenocarcinoma, thyroid, follicular carcinoma, undifferentiated carcinoma, papillary carcinoma, seminoma, melanoma, sarcoma, bladder carcinoma, liver carcinoma and biliary passages, kidney carcinoma, renal, pancreatic, myeloid disorders, lymphoma, hairy cells, buccal cavity, naso-pharyngeal, pharynx, lip, tongue, mouth, small intestine, colon-rectum, large intestine, rectum, brain and central nervous system, Hodgkin's and leukemia.